Combining Biomarkers (AFP, AFP-L3, and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma

NCT04414956 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1418

Last updated 2020-06-04

No results posted yet for this study

Summary

In this study, three biomarkers tests (AFP, AFP-L3 and PIVKA-II) and abdominal sonography or CT scans are performed every 6 months to detect hepatocellular carcinoma (HCC) early in patients with cirrhosis, a high-risk group of HCC. The aim of this study is to confirm the early HCC diagnosis rate in patients with cirrhosis and compare the detection efficacy between tests.

Conditions

Interventions

DIAGNOSTIC_TEST

AFP-L3

AFP-L3 will be tested using serum sample every 6 months.

DIAGNOSTIC_TEST

AFP

AFP will be tested using serum sample every 6 months.

DIAGNOSTIC_TEST

PIVKA-II

PIVKA-II will be tested using serum sample every 6 months.

DIAGNOSTIC_TEST

Sonography

Sonography will be tested by experts every 6 months.

DIAGNOSTIC_TEST

CT

Contrast-enhanced CT will be tested annually.

Sponsors & Collaborators

  • Korea University Ansan Hospital

    collaborator OTHER
  • Soonchunhyang University Hospital

    collaborator OTHER
  • Korea University Guro Hospital

    collaborator OTHER
  • The Catholic University of Korea

    collaborator OTHER
  • Samsung Medical Center

    collaborator OTHER
  • Asan Medical Center

    collaborator OTHER
  • Korea University Anam Hospital

    collaborator OTHER
  • Keimyung University Dongsan Medical Center

    collaborator OTHER
  • Severance Hospital

    collaborator OTHER
  • Hanyang University

    collaborator OTHER
  • Konkuk University Hospital

    collaborator OTHER
  • Seoul National University Hospital

    collaborator OTHER
  • Inje University

    collaborator OTHER
  • Chung-Ang University Hosptial, Chung-Ang University College of Medicine

    collaborator OTHER
  • Korea University

    lead OTHER

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-01
Primary Completion
2023-06-30
Completion
2026-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04414956 on ClinicalTrials.gov